Jiri Kaderabek / Shutterstock.com
Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh.
ore and more pharmaceutical companies are turning to the new US Patent and Trademark Office (USPTO) proceedings available under the America Invents Act (AIA) as a way to attack the validity of bio/pharma patents.
To date, inter partes review (IPR) proceedings, in particular, have been the focal point of post-AIA activity and, according to Patent Trial and Appeal Board (PTAB) statistics dated September 18 this year, 5.6% of IPR petitions relate to bio/pharma patents.
Those petitions are increasing. Over the past five and a half months alone, the number of IPR petitions of bio/pharma patents has almost doubled.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
biotechnology; pharma patents; patents; pharmaceuticals; USPTO; PTAB